Literature DB >> 23580872

Febrile neutropenia studies in Brazil - treatment and cost management based on analyses of cases.

Marcelo Bellesso1.   

Abstract

Entities:  

Year:  2013        PMID： 23580872      PMCID： PMC3621623          DOI： 10.5581/1516-8484.20130002

Source DB:  PubMed          Journal:  Rev Bras Hematol Hemoter        ISSN： 1516-8484


× No keyword cloud information.
  17 in total

1.  Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.

Authors:  Corrado Girmenia; Eleonora Russo; Ida Carmosino; Massimo Breccia; Francesco Dragoni; Roberto Latagliata; Sergio Mecarocci; Salvatore Giacomo Morano; Caterina Stefanizzi; Giuliana Alimena
Journal:  Ann Hematol       Date:  2007-01-16       Impact factor: 3.673

2.  The feasibility of early discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies.

Authors:  Catherine Cordonnier
Journal:  Haematologica       Date:  2006-02       Impact factor: 9.941

3.  Factors affecting mortality of gram-negative rod bacteremia.

Authors:  R E Bryant; A F Hood; C E Hood; M G Koenig
Journal:  Arch Intern Med       Date:  1971-01

4.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

Authors:  G P Bodey; M Buckley; Y S Sathe; E J Freireich
Journal:  Ann Intern Med       Date:  1966-02       Impact factor: 25.391

5.  The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation.

Authors:  J A Talcott; R Finberg; R J Mayer; L Goldman
Journal:  Arch Intern Med       Date:  1988-12

6.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

7.  Outpatient treatment with intravenous antimicrobial therapy and oral levofloxacin in patients with febrile neutropenia and hematological malignancies.

Authors:  Marcelo Bellesso; Silvia Figueiredo Costa; Luis Fernando Pracchia; Lucia Cristina Santos Dias; Dalton Chamone; Pedro Enrique Dorlhiac-Llacer
Journal:  Ann Hematol       Date:  2010-09-18       Impact factor: 3.673

8.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Authors:  J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

9.  Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients.

Authors:  Luciano de Souza Viana; José Carlos Serufo; Manoel Otávio da Costa Rocha; Renato Nogueira Costa; Roberto Carlos Duarte
Journal:  Support Care Cancer       Date:  2007-10-25       Impact factor: 3.603

10.  Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.

Authors:  Nirmala Devi Baskaran; Gin Gin Gan; Kamarulzaman Adeeba
Journal:  Ann Hematol       Date:  2008-04-24       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.